The estimated Net Worth of Scott Bradford Patterson is at least $412 Mille dollars as of 10 December 2013. Scott Patterson owns over 334,979 units of LadRx Corp stock worth over $411,984 and over the last 12 years Scott sold CYTR stock worth over $0.
Sign up
Scott Patterson CYTR stock SEC Form 4 insiders trading
Scott has made over 17 trades of the LadRx Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently Scott bought 334,979 units of CYTR stock worth $803,950 on 10 December 2013.
The largest trade Scott's ever made was buying 1,200,000 units of LadRx Corp stock on 18 October 2012 worth over $3,000,000. On average, Scott trades about 174,357 units every 33 days since 2012. As of 10 December 2013 Scott still owns at least 4,577,605 units of LadRx Corp stock.
You can see the complete history of Scott Patterson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Scott Patterson's mailing address?
Scott's mailing address filed with the SEC is 128 SPOONBILL COURT, , JUPITER, FL, 33458-8879.
Insiders trading at LadRx Corp
Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson e Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.
What does LadRx Corp's logo look like?
Complete history of Scott Patterson stock trades at LadRx Corp
LadRx Corp executives and stock owners
LadRx Corp executives and other stock owners filed with the SEC include:
-
Steven Kriegsman,
Chairman of the Board, Chief Executive Officer -
Steven A. Kriegsman,
Chief Exec. Officer -
John Caloz,
Chief Financial Officer, Chief Accounting Officer, IR Contact Officer -
John Y. Caloz,
CFO, Treasurer & Sr. VP -
Louis Ignarro,
Independent Director -
Joel Caldwell,
Director -
Earl Brien,
Director -
Dr. Felix Kratz Ph.D.,
Sr. VP, Drug Devel. -
Cristina Newman,
Corp. Sec. -
Terri Stevens,
Chief Bus. Officer -
Molly Painter,
Pres of USA and Head of Launch & Commercial Operations -
Molly Carey Poarch,
Global & U.S. Head of Corp. Communications -
Jennifer K. Simpson,
Director -
Anita J Chawla,
Director -
Daniel J Levitt,
Chief Medical Officer -
Joseph Rubinfeld,
Director -
Olivia C Ware,
Chief Commercial Officer -
Douglas Scott Wieland,
Sr. VP - Drug Development -
Felix Kratz,
Vice President Drug Discovery -
Herbert H Jr Mcdade,
-
Alexander L Cappello,
Director -
Raymond C Jr Carnahan,
-
Ben Levin,
Gen.Cnsl/VP Legal Affairs/Secy -
Eric Jay Selter,
Director -
Cheryl Cohen,
Director -
Scott Bradford Patterson,
10% owner -
Marvin R Selter,
Director -
Richard J Wennekamp,
Director -
Max Link,
Director -
David Scott Geyer,
Sr. V.P. of Manufacturing -
Mitchell K Fogelman,
Chief Financial Officer -
Jack R Barber,
Sr VP - Drug Development -
Shi Chung Ng,
Sr. VP Research & Development -
Matt Natalizio,
Chief Financial Officer -
Mark Tepper,
Vice President -
Stephen Snowdy,
Chief Executive Officer